Short Interest in Immunic, Inc. (NASDAQ:IMUX) Decreases By 32.0%

Immunic, Inc. (NASDAQ:IMUX) was the target of a large decline in short interest in the month of February. As of February 15th, there was short interest totalling 2,550,000 shares, a decline of 32.0% from the January 31st total of 3,750,000 shares. Based on an average daily volume of 933,800 shares, the short-interest ratio is currently 2.7 days.

Immunic Stock Up 0.9 %

NASDAQ IMUX opened at $1.17 on Wednesday. Immunic has a twelve month low of $0.92 and a twelve month high of $2.11. The firm has a market capitalization of $105.39 million, a PE ratio of -0.95 and a beta of 1.87. The stock’s 50 day moving average is $1.04 and its 200 day moving average is $1.25.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the company. StockNews.com cut Immunic from a “hold” rating to a “sell” rating in a research note on Saturday, February 22nd. D. Boral Capital reiterated a “buy” rating and issued a $17.00 price objective on shares of Immunic in a research report on Wednesday, February 26th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Immunic in a research report on Friday, February 21st. One analyst has rated the stock with a sell rating, six have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Immunic presently has an average rating of “Buy” and an average price target of $12.67.

Institutional Investors Weigh In On Immunic

Several hedge funds have recently made changes to their positions in IMUX. Invesco Ltd. bought a new stake in shares of Immunic during the fourth quarter valued at approximately $37,000. Virtu Financial LLC bought a new stake in shares of Immunic during the third quarter valued at approximately $50,000. HB Wealth Management LLC bought a new stake in shares of Immunic during the fourth quarter valued at approximately $81,000. Barclays PLC bought a new stake in shares of Immunic during the fourth quarter valued at approximately $84,000. Finally, Jane Street Group LLC boosted its position in shares of Immunic by 121.4% during the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock valued at $116,000 after purchasing an additional 38,553 shares in the last quarter. 51.82% of the stock is currently owned by institutional investors.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.